Olon is an Italian company world leader in the Active Pharmaceutical Ingredients (APIs) production, using synthetic and biological processes for Generic market as well as in Contract Development and Manufacturing (CDMO). The Dossier Unit has been further enlarged, considering the development of the Finished Drug Formulations (FDFs) and the preparation of the Common Technical Documents (CTD) dossier.

With a 2019 turnover of 500 Mio$, Olon supplies more than 295 APIs for the Generic market.

Thanks to 2000 employees, and to the highly qualified R&D team – more than 200 people – Olon can offer complete integrated packages and services to support the full development of APIs based on strong knowledge in both Chemical and Biological process, in a full cGMP’s environment including a complete regulatory coverage.

Considering human safety and environmental security, Olon handles different and not-common manufacturing process technologies, such as Fluorination, Carbonylation and Fermentation.

Headquartered in Rodano (Milan, Italy), Olon has 11 manufacturing facilities – 8 located in Italy, 1 in Spain, 1 in USA and 1 in India – compliant with international requirements, and 3 branch offices: Hamburg (D), Florham Park NJ (USA) and Shanghai (China).

All manufacturing sites are regularly inspected by the most important national and international Authorities, and regularly audited by our partners and customers. All plants are FDA-inspected and self-identified under GDUFA.

Besides pharmaceutical certifications, Olon has dedicated areas for food-grade manufacturing and complies with KOSHER, AHLAL and from 2018-Q2 with FSSC 22.000.

To be highlighted Olon’s growing cooperation with Universities: University of Milan (Italy), Milan Politecnico (Italy), University of Pavia (Italy) University of Murcia (Spain), PROMIDIS (Milan University spin-off) and University of Naples (Italy).